The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor.

MEK inhibitor has been highlighted as a promising anti-tumor drug but its effect has been reported as varying over a wide range depending on patho-physiological conditions. In this study, we employed a systems approach by combining biochemical experimentation with in silico simulations to investigate the resistance mechanism and functional consequences of MEK inhibitor. To this end, we have developed an extended integrative model of ERK and PI3K signaling pathways by considering the crosstalk between Ras and PI3K, and analyzed the resistance mechanism to the MEK inhibitor under various mutational conditions. We found that the phospho-Akt level under the Raf mutation was remarkably augmented by MEK inhibitor, while the phospho-ERK level was almost completely repressed. These results suggest that bypassing of the ERK signal to the PI3K signal causes the resistance to the MEK inhibitor in a complex oncogenic signaling network. We further investigated the underlying mechanism of the drug resistance and revealed that the MEK inhibitor disrupts the negative feedback loops from ERK to SOS and GAB1, but activates the positive feedback loop composed of GAB1, Ras, and PI3K, which induces the bypass of the ERK signal to the PI3K signal. Based on these core feedback circuits, we suggested promising candidates for combination therapy and examined the improved inhibitory effects.

[1]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[2]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[3]  W. Sellers,et al.  MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.

[4]  P. Hawkins,et al.  Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. , 2000, Cell.

[5]  P. Hawkins,et al.  Activation of phosphoinositide 3-kinase gamma by Ras. , 2002, Current biology : CB.

[6]  Jens Timmer,et al.  Systems-level interactions between insulin–EGF networks amplify mitogenic signaling , 2009, Molecular systems biology.

[7]  M. Wildermuth,et al.  Metabolic control analysis: biological applications and insights , 2000, Genome Biology.

[8]  Michael J. Fry,et al.  Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.

[9]  Laura M. Heiser,et al.  Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. , 2009, Cancer research.

[10]  J. Hecht,et al.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Hawkins,et al.  Activation of Phosphoinositide 3-Kinase γ by Ras , 2002, Current Biology.

[12]  S. Cook,et al.  Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM , 2008, Oncogene.

[13]  W. Sellers,et al.  PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. , 2009, Cancer research.

[14]  A. Wagner.  Robustness against mutations in genetic networks of yeast , 2000, Nature Genetics.

[15]  Kwang-Hyun Cho,et al.  A hidden incoherent switch regulates RCAN1 in the calcineurin–NFAT signaling network , 2011, Journal of Cell Science.

[16]  Balázs Papp,et al.  Systems-biology approaches for predicting genomic evolution , 2011, Nature Reviews Genetics.

[17]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[18]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[19]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[20]  Robert A. Gatenby,et al.  Environment-mediated drug resistance: a major contributor to minimal residual disease , 2009, Nature Reviews Cancer.

[21]  J. Lehár,et al.  High-order combination effects and biological robustness , 2008, Molecular systems biology.

[22]  Yiling Lu,et al.  Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.

[23]  Prahlad T. Ram,et al.  Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. , 2010, Cancer research.

[24]  Eric B Haura,et al.  A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[25]  Patricia M. LoRusso,et al.  Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers , 2010, Clinical Cancer Research.

[26]  Nathanael Gray,et al.  Factors underlying sensitivity of cancers to small-molecule kinase inhibitors , 2009, Nature Reviews Drug Discovery.

[27]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[28]  S. Lovell,et al.  Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site , 2004, BMC Biology.

[29]  J. Blenis,et al.  The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.

[30]  Phillip T. Hawkins,et al.  Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ , 2000, Cell.

[31]  Vivienne Marsh,et al.  Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.

[32]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[33]  Alan P. Brown,et al.  Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration , 2007, Cancer Chemotherapy and Pharmacology.

[34]  I. Lax,et al.  The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway , 2004, BMC Biology.

[35]  A. Iafrate,et al.  BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation , 2010, Science Signaling.

[36]  R. Hamatake,et al.  RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. , 2009, Cancer research.

[37]  W. Franklin,et al.  Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.

[39]  Ultan McDermott,et al.  Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. , 2008, Cancer research.

[40]  H. Kitano.  A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.